Latest Manufacturing News

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

Talga Group has achieved critical milestones with environmental permits and a 25-year mining concession for its Nunasvaara South graphite mine, alongside securing a €70 million EU Innovation Fund grant for its Luleå Anode Refinery, positioning it at the forefront of Europe's battery materials supply chain.

Renascor Resources advances its Battery Anode Material project with the Early Contractor Involvement phase nearing completion, alongside securing major project status and progressing its Purified Spherical Graphite demonstration plant.

FinTech Chain Limited reports a robust increase in cash balances and positive operating cash flow for Q3 2024, alongside new contract wins and ongoing legal proceedings related to a past misappropriation case.

Cann Group Limited reported a positive operating cash flow for Q2 2024, driven by an R&D tax credit refund, while ramping up production and navigating pricing pressures in the medicinal cannabis market.

Lykos Metals Limited reports significant high-grade mineral findings at its Sinjakovo Project and extends its Jezero exploration permit, alongside key board appointments and cost restructuring.

DTI Group Limited has inked a global Master Framework Agreement with Siemens Mobility GmbH, streamlining worldwide purchasing and opening doors to new rail and bus sector projects. Despite a modest cash balance, DTI is advancing its flagship software, positioning itself for growth.

Electro Optic Systems (EOS) has completed the divestment of its EM Solutions subsidiary for $158.6 million, wiping out all borrowings and positioning itself with a strong cash balance of approximately $128 million. The company is actively pursuing significant defence contracts and expanding its manufacturing footprint.

Energy Technologies Limited reported a 17.5% increase in unaudited sales revenue for 2Q FY2025, driven by a new cable supply contract and a robust order book, signaling positive momentum amid a strategic business plan revision.

NOVONIX has advanced its position in the battery materials sector with a conditional US$754 million loan commitment from the U.S. Department of Energy and binding offtake agreements with automotive giants Stellantis and PowerCo. These milestones underpin its expansion plans for synthetic graphite production in North America.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.

Tissue Repair Limited reports initial patient enrolment in its pivotal Phase 3 trial for TR987®, alongside a robust 35% quarterly sales increase for its TR Pro+® product. The company is also advancing manufacturing and distribution strategies to support growth.